Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 59.8 16.9 353.9% View Chart
P/BV x 13.8 3.7 376.9% View Chart
Dividend Yield % 0.4 0.3 154.0%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
AUROBINDO PHARMA
Mar-19
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639830 197.5%   
Low Rs1,115527 211.5%   
Sales per share (Unadj.) Rs186.3333.9 55.8%  
Earnings per share (Unadj.) Rs51.040.4 126.3%  
Cash flow per share (Unadj.) Rs57.351.8 110.7%  
Dividends per share (Unadj.) Rs16.002.50 640.0%  
Dividend yield (eoy) %1.20.4 315.3%  
Book value per share (Unadj.) Rs261.8237.1 110.4%  
Shares outstanding (eoy) m265.47585.91 45.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.42.0 363.7%   
Avg P/E ratio x27.016.8 160.7%  
P/CF ratio (eoy) x24.013.1 183.3%  
Price / Book Value ratio x5.32.9 183.8%  
Dividend payout %31.46.2 506.9%   
Avg Mkt Cap Rs m365,592397,569 92.0%   
No. of employees `00011.817.9 66.4%   
Total wages/salary Rs m5,42325,849 21.0%   
Avg. sales/employee Rs Th4,175.110,956.9 38.1%   
Avg. wages/employee Rs Th457.71,447.7 31.6%   
Avg. net profit/employee Rs Th1,141.81,324.3 86.2%   
INCOME DATA
Net Sales Rs m49,463195,636 25.3%  
Other income Rs m1,5561,553 100.2%   
Total revenues Rs m51,019197,189 25.9%   
Gross profit Rs m18,71839,519 47.4%  
Depreciation Rs m1,6896,680 25.3%   
Interest Rs m352,626 1.3%   
Profit before tax Rs m18,55131,767 58.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m5,0237,269 69.1%   
Profit after tax Rs m13,52723,645 57.2%  
Gross profit margin %37.820.2 187.3%  
Effective tax rate %27.122.9 118.3%   
Net profit margin %27.312.1 226.3%  
BALANCE SHEET DATA
Current assets Rs m46,501153,645 30.3%   
Current liabilities Rs m8,468120,429 7.0%   
Net working cap to sales %76.917.0 452.9%  
Current ratio x5.51.3 430.4%  
Inventory Days Days131135 96.7%  
Debtors Days Days8664 134.8%  
Net fixed assets Rs m25,797103,909 24.8%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m68,962138,322 49.9%   
Net worth Rs m69,493138,908 50.0%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m80,383264,544 30.4%  
Interest coverage x531.013.1 4,054.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 83.2%   
Return on assets %16.99.9 169.9%  
Return on equity %19.517.0 114.4%  
Return on capital %26.723.8 112.2%  
Exports to sales %049.6 0.0%   
Imports to sales %24.618.8 131.2%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs m12,18736,741 33.2%   
Fx inflow Rs m41,23897,316 42.4%   
Fx outflow Rs m12,40540,589 30.6%   
Net fx Rs m28,83356,727 50.8%   
CASH FLOW
From Operations Rs m9,54316,220 58.8%  
From Investments Rs m-6,854-28,768 23.8%  
From Financial Activity Rs m-2,45919,191 -12.8%  
Net Cashflow Rs m2306,656 3.4%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  NEULAND LABS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Shine More than Gold After Diwali(Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

How to Build the Best Trading System(Fast Profits Daily)

Nov 20, 2020

In this video, I'll show you how to make the best trading system.

An Eraser and Some Pencils(The Honest Truth)

Nov 17, 2020

Ajit Dayal on the road ahead for the world after covid.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 27, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - DR. REDDYS LAB COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS